Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.49 |
| ▸ | ITGAV | P06756 | 20/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644035 | 0.92 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7702988 | 0.92 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4640085 | 0.88 | ITGAV (0.38) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4640112 | 0.86 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4640260 | 0.86 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6884447 | 0.85 | ITGB3 (0.39) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6802240 | 0.85 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4641449 | 0.85 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6802237 | 0.85 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6811091 | 0.84 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | claimed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | claimed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | claimed |
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-6992187-B2 | Process for the preparation of birthonectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20040248907-A1 | Process for the preparation of birthonectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1315728-B1 | PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2004-10-27 | — | — | EP | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248907-A1 | Process for the preparation of birthonectin receptor antagonists | NGFR, TNFSF11, NRP1 | ITGB3 908/4885ITGAV 506/4885ITGA2B 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.